EUCTR2022-001298-30-NL进行中（未招募）1 期
What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention? - WOEST 3
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. =18 years of age
- •2. Undergoing PCI or presenting with ACS with elevated cardiac markers (CK/CK-MB, troponin)
- •3. History of or newly diagnosed atrial fibrillation or flutter with a long-term (= 1 year) indication for OAC
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1500
排除标准
- •1. Contra indication to edoxaban
- •2. <3 months after any stroke
- •3. <3 months after venous thrombo embolism
- •4. Mechanical heart valve prosthesis
- •5. Moderate to severe mitral valve stenosis
- •6. Intracardiac thrombus
研究者
相似试验
撤回
4 期
What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants?myocardial infarctionNL-OMON49131Sint Antonius Ziekenhuis2,500
进行中（未招募）
1 期
What is the optimal blood thinner strategy in patients with atrial fibrillation presenting with a heart attack?Acute coronary syndrome in patients with known or new atrial fibrillation with indication for oral anticoagulantsEUCTR2019-004805-28-NLSt. Antonius Hospital2,500
招募中
1 期
WOEST-3Atrial fibrillationAcute coronary syndromeChronic coronary syndromeCTIS2022-502140-13-00St Antonius Hospital2,550
招募中
4 期
What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention?coronary artery disease10011082atrial fibrillationNL-OMON51815Sint Antonius Ziekenhuis1,500
尚未招募
Unknown
Optimal antithrombotic strategy for treatment of atherosclerotic cardiovascular disease – comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study)KCT0008458Seoul National University Bundang Hospital2,758